Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 81 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.
Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis L, Di Santo N, Zielinski MA, Agarwal N
Eur J Cancer, 213:115078, 20 Oct 2024
Cited by: 0 articles | PMID: 39486165
Add to export list
Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study.
Monteiro FSM, Alencar Junior AM, da Trindade KM, Rebelatto TF, Maluf FC, Gazzola AA, Barrios PM, Bellmunt J, de Jesus RG, Silva GEB, Teixeira Junior AAL, Spiess PE, Fay AP
Oncologist, oyae220, 02 Sep 2024
Cited by: 0 articles | PMID: 39222919
Add to export list
The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.
Souza VC, Monteiro FSM, Maluf FC, Werutsky G, Fabrício VC, Gidekel R, Gandur-Quiroga MN, Freitas MRP, Luz M, Campos-Gomez S, Junior JAR, Bastos DA, Sade JP, da Trindade KM, Mota ACA, Fernandes RC, Ruíz AOB, Pereira E Silva BD, de Oliveira FNG, [...] Fay AP
Clin Genitourin Cancer, 22(5):102174, 25 Jul 2024
Cited by: 0 articles | PMID: 39181783
Add to export list
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, [...] Fizazi K
Future Oncol, 20(29):2123-2135, 12 Jul 2024
Cited by: 0 articles | PMID: 38995237 | PMCID: PMC11524199
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The impact of a breast cancer diagnosis on marital outcomes and factors associated with divorce and separation.
Werutsky G, Lopes M, de Jesus RG, Gazola AA, Pellegrini RA, Rebelatto TF, Freitas LVW, Heck AP, da Silva AF, Rodrigues MF, Gössling G, Giacomazzi J, Rocha MS, Rosa DD, Barrios CH, Cronemberger EH, Queiroz GS, Bines J, Simon SD, Fay AP
Rev Bras Ginecol Obstet, 46:e-rbgo60, 27 Jun 2024
Cited by: 0 articles | PMID: 38994465 | PMCID: PMC11239212
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.
Incorvaia L, Monteiro FSM, Massari F, Park SH, Roviello G, Fiala O, Myint ZW, Kucharz J, Molina-Cerrillo J, Santini D, Buttner T, Poprach A, Kopecky J, Zeppellini A, Pichler M, Buchler T, Pichler R, Facchini G, Fay AP, [...] Santoni M
Cancer Immunol Immunother, 73(8):142, 04 Jun 2024
Cited by: 0 articles | PMID: 38832989 | PMCID: PMC11150359
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy.
Shore ND, Broder MS, Barata PC, Crispino T, Fay AP, Lloyd J, Mellado B, Matsubara N, Pfanzelter N, Schlack K, Sieber P, Soares A, Dalglish H, Niyazov A, Shaman S, Zielinski MA, Chang J, Agarwal N
Eur Urol Oncol, S2588-9311(24)00140-8, 11 Jun 2024
Cited by: 0 articles | PMID: 38866640
Add to export list
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, [...] Agarwal N
Nat Med, 30(5):1505, 01 May 2024
Cited by: 0 articles | PMID: 38297094 | PMCID: PMC11108769
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, [...] Bellmunt J
Cancer Immunol Immunother, 73(6):106, 18 Apr 2024
Cited by: 2 articles | PMID: 38634928 | PMCID: PMC11026312
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.
Soares A, Monteiro FSM, da Trindade KM, Silva AGE, Cardoso APG, Sasse AD, Fay AP, Carneiro APCD, Alencar Junior AM, de Andrade Mota AC, Santucci B, da Motta Girardi D, Herchenhorn D, Araújo DV, Jardim DL, Bastos DA, Rosa DR, Schutz FA, Kater FR, [...] de Cássio Zequi S
J Cancer Res Clin Oncol, 150(4):183, 09 Apr 2024
Cited by: 0 articles | PMID: 38594593 | PMCID: PMC11003910
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, [...] KEYNOTE-564 Investigators
N Engl J Med, 390(15):1359-1371, 01 Apr 2024
Cited by: 14 articles | PMID: 38631003
Add to export list
Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.
Chen N, McGrath CB, Ericsson CI, Vaselkiv JB, Rencsok EM, Stopsack KH, Guard HE, Autio KA, Rathkopf DE, Enting D, Bitting RL, Mateo J, Githiaka CW, Chi KN, Cheng HH, Davis ID, Anderson SG, Badal SAM, Bjartell A, [...] IRONMAN Registry
Cancer Epidemiol Biomarkers Prev, 33(3):419-425, 01 Mar 2024
Cited by: 0 articles | PMID: 38189661 | PMCID: PMC10922505
Add to export list Free full text in Europe PMC
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.
Monteiro FSM, Fiala O, Massari F, Myint ZW, Kopecky J, Kucharz J, Büttner T, Grande E, Bourlon MT, Molina-Cerrillo J, Pichler R, Buchler T, Seront E, Ansari J, Bamias A, Bhuva D, Vau N, Porta C, Fay AP, Santoni M
Clin Genitourin Cancer, 22(2):305-314.e3, 24 Nov 2023
Cited by: 3 articles | PMID: 38087702
Add to export list
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, [...] Agarwal N
Nat Med, 30(1):257-264, 04 Dec 2023
Cited by: 14 articles | PMID: 38049622 | PMCID: PMC10803259
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis.
Tariki MS, Barberan CCG, Torres JA, Ruano APC, Ferreira Costa DJ, Braun AC, da Silva Alves V, de Cássio Zequi S, da Costa WH, Fay AP, Torrezan G, Carraro DM, Domingos Chinen LT
Pathol Res Pract, 253:154918, 10 Nov 2023
Cited by: 1 article | PMID: 37995423
Add to export list
Germline EGFR Mutations and Familial Lung Cancer.
Oxnard GR, Chen R, Pharr JC, Koeller DR, Bertram AA, Dahlberg SE, Rainville I, Shane-Carson K, Taylor KA, Sable-Hunt A, Sholl LM, Teerlink CC, Thomas A, Cannon-Albright LA, Fay AP, Ashton-Prolla P, Yang H, Salvatore MM, Addario BJ, [...] Garber JE
J Clin Oncol, 41(34):5274-5284, 23 Oct 2023
Cited by: 5 articles | PMID: 37579253
Add to export list
Core Needle Biopsy Accuracy for Androgen Receptor Expression in Invasive Breast Cancer.
Santos MMD, Frasson AL, Silva VDD, Maciel ACA, Watte G, Werutsky G, Reinert T, Fay AP
Rev Bras Ginecol Obstet, 45(9):e535-e541, 01 Sep 2023
Cited by: 0 articles | PMID: 37846186 | PMCID: PMC10579921
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios GA, Dionese M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Quiroga MNG, Gilbert D, Popovic L, Grande E, [...] Santoni M
Cancer Immunol Immunother, 72(11):3665-3682, 07 Sep 2023
Cited by: 8 articles | PMID: 37676282 | PMCID: PMC10992198
Add to export list Free full text in Europe PMC
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, [...] Fizazi K
Lancet, 402(10398):291-303, 04 Jun 2023
Cited by: 90 articles | PMID: 37285865
Add to export list
IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer.
Mucci LA, Vinson J, Gold T, Gerke T, Filipenko J, Green RM, Anderson SG, Badal S, Bjartell A, Chi KN, Davis ID, Enting D, Fay AP, Lazarus J, Mateo J, McDermott R, Odedina FT, Olmos D, Omlin A, [...] IRONMAN Global Team
JCO Glob Oncol, 8:e2200154, 01 Nov 2022
Cited by: 4 articles | PMID: 36332173 | PMCID: PMC9668562
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515).
Bastos DA, Gongora ABL, Dzik C, Jardim DL, Piva M, Carcano FM, Bertollo G, Trindade K, Fontes MS, Soares A, Reinert T, De Cassia Costamilan R, Villarroel RU, Watarai G, Gazola AA, Preto DDA, Mutti H, Bonalumi Dos Santos M, Mariano RC, [...] Fay AP
Clin Genitourin Cancer, 21(3):e104-e113, 12 Nov 2022
Cited by: 1 article | PMID: 36509612
Add to export list
"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil".
Jardim DL, Gonçalves E Silva A, Pompeo ASFL, Sarkis AS, Cardoso APG, Sasse AD, Fay AP, Soares A, Pompeo ACL, Carneiro A, Kann AG, Fogassa C, De Freitas CH, Chade DC, Herchenhorn D, De Almeida DVP, Da Rosa DAR, Wiermann EG, Schutz FAB, [...] Maluf F
Clin Genitourin Cancer, 21(2):e58-e69, 10 Sep 2022
Cited by: 0 articles | PMID: 36266221
Add to export list
Rapid and low-cost liquid biopsy with ATR-FTIR spectroscopy to discriminate the molecular subtypes of breast cancer.
Pereira de Souza NM, Machado BH, Padoin LV, Prá D, Fay AP, Corbellini VA, Rieger A
Talanta, 254:123858, 21 Aug 2022
Cited by: 3 articles | PMID: 36470017
Add to export list
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.
Baca SC, Singler C, Zacharia S, Seo JH, Morova T, Hach F, Ding Y, Schwarz T, Huang CF, Anderson J, Fay AP, Kalita C, Groha S, Pomerantz MM, Wang V, Linder S, Sweeney CJ, Zwart W, Lack NA, [...] Freedman ML
Nat Genet, 54(9):1364-1375, 07 Sep 2022
Cited by: 22 articles | PMID: 36071171 | PMCID: PMC9784646
Add to export list Free full text in Europe PMC
Intercomparison of radiosensitization induced by gold and iron oxide nanoparticles in human glioblastoma cells irradiated by 6 MV photons.
Guerra DB, Oliveira EMN, Sonntag AR, Sbaraine P, Fay AP, Morrone FB, Papaléo RM
Sci Rep, 12(1):9602, 10 Jun 2022
Cited by: 9 articles | PMID: 35688846 | PMCID: PMC9187689
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 81 results

1 2 3 Next ...

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.

Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study.

The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.

The impact of a breast cancer diagnosis on marital outcomes and factors associated with divorce and separation.

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.

Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy.

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.

Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.

Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis.

Germline EGFR Mutations and Familial Lung Cancer.

Core Needle Biopsy Accuracy for Androgen Receptor Expression in Invasive Breast Cancer.

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.

IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer.

Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515).

"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil".

Rapid and low-cost liquid biopsy with ATR-FTIR spectroscopy to discriminate the molecular subtypes of breast cancer.

Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.

Intercomparison of radiosensitization induced by gold and iron oxide nanoparticles in human glioblastoma cells irradiated by 6 MV photons.

Partnerships & funding